- Home
- TENX vs CARA Comparison
TENX vs CARA Comparison
Compare TENX & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- CARA
- Stock Information
- Founded
- TENX 1967
- CARA 2004
- Country
- TENX United States
- CARA United States
- Employees
- TENX N/A
- CARA N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- CARA Health Care
- Exchange
- TENX Nasdaq
- CARA Nasdaq
- Market Cap
- TENX 21.1M
- CARA 23.1M
- IPO Year
- TENX N/A
- CARA 2014
- Fundamental
- Price
- TENX $6.02
- CARA $4.94
- Analyst Decision
- TENX Strong Buy
- CARA Hold
- Analyst Count
- TENX 3
- CARA 3
- Target Price
- TENX $16.00
- CARA $12.00
- AVG Volume (30 Days)
- TENX 56.1K
- CARA 16.0K
- Earning Date
- TENX 03-27-2025
- CARA 03-14-2025
- Dividend Yield
- TENX N/A
- CARA N/A
- EPS Growth
- TENX N/A
- CARA N/A
- EPS
- TENX N/A
- CARA N/A
- Revenue
- TENX N/A
- CARA $8,686,000.00
- Revenue This Year
- TENX N/A
- CARA N/A
- Revenue Next Year
- TENX N/A
- CARA N/A
- P/E Ratio
- TENX N/A
- CARA N/A
- Revenue Growth
- TENX N/A
- CARA N/A
- 52 Week Low
- TENX $2.77
- CARA $2.71
- 52 Week High
- TENX $7.89
- CARA $12.12
- Technical
- Relative Strength Index (RSI)
- TENX 45.53
- CARA 47.13
- Support Level
- TENX $5.91
- CARA $4.83
- Resistance Level
- TENX $6.37
- CARA $4.95
- Average True Range (ATR)
- TENX 0.47
- CARA 0.22
- MACD
- TENX -0.05
- CARA -0.03
- Stochastic Oscillator
- TENX 25.58
- CARA 51.72
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.